Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.

Refractory chronic cough affects approximately 2-3 million adults in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is highly disruptive and ...

On-demand video webcast now available here AURORA, CO / ACCESS Newswire / February 19, 2025 / Exxel Pharma("Exxel" or the ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Refractory chronic cough represents a significant unmet ... to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders, today provided an overview of its EX937 ...

On-demand video webcast now available here AURORA, CO / ACCESS Newswire / February 19, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeuti ...

Exxel Pharma is a privately held pharmaceutical company focused on developing innovative therapeutics for neuronal hypersensitivity ... of EX937 for refractory chronic cough, a significant unmet ...

SINGAPORE: Codeine cough syrup made up the majority of illegal ... This is a severe hypersensitivity reaction characterised by skin rash, blood abnormalities and injury to the liver and/or ...